Lorenzo Gaetani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9080707/publications.pdf

Version: 2024-02-01

45 papers	1,951 citations	394421 19 h-index	276875 41 g-index
46 all docs	46 docs citations	46 times ranked	3126 citing authors

#	Article	IF	Citations
1	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. Journal of Neurology, 2022, 269, 3129-3135.	3.6	6
2	Blood biomarkers may distinguish among dementia disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 571-571.	1.9	1
3	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 2022, 37, 669-683.	3.9	30
4	NfL as Analogue of C-Reactive Protein in Neurologic Diseases. Neurology, 2022, 98, 911-912.	1.1	6
5	Î±-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies. Neurology, 2022, 99, 195-205.	1.1	45
6	Phosphatidylethanolamine Binding ProteinÂ1 (PEBP1) in Alzheimerâ€™s Disease: ELISA Development and Clinical Validation. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	1
7	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	3.3	12
8	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. Neural Regeneration Research, 2021, 16, 36.	3.0	23
9	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimerâ€™s disease. Amino Acids, 2021, 53, 435-449.	2.7	14
10	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimerâ€™s Disease and Other Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 647783.	2.8	17
11	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. International Journal of Molecular Sciences, 2021, 22, 4440.	4.1	17
12	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. Frontiers in Neuroscience, 2021, 15, 672954.	2.8	19
13	The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimerâ€™s Disease, Parkinsonâ€™s Disease and Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 4958.	4.1	28
14	Neuroinflammation and Alzheimerâ€™s Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	4.1	34
15	A blood test for Alzheimer's disease: a step forward. Lancet Neurology, The, 2021, 20, 691-693.	10.2	1
16	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. International Journal of Molecular Sciences, 2021, 22, 9753.	4.1	17
17	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. Journal of Neuroinflammation, 2021, 18, 259.	7.2	20
18	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	6.4	38

#	Article	IF	Citations
19	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. Journal of Neuroimmunology, 2020, 339, 577108.	2.3	31
20	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 2020, 41, 1023-1037.	8.7	48
21	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140537.	2.3	19
22	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. Clinica Chimica Acta, 2020, 506, 55-66.	1.1	2
23	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 157.	4.8	35
24	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3848-3857.	7.1	58
25	The Challenge of Disease-Modifying Therapies in Parkinsonâ€™s Disease: Role of CSF Biomarkers. Biomolecules, 2020, 10, 335.	4.0	25
26	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	2.0	20
27	Serum neurofilament light chain as a preclinical marker of neurodegeneration. Lancet Neurology, The, 2019, 18, 1070-1071.	10.2	9
28	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	3.6	41
29	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	1.9	623
30	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	10.2	393
31	Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. Neural Regeneration Research, 2019, 14, 77.	3.0	4
32	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. Journal of Neurology, 2018, 265, 522-529.	3.6	5
33	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. Neurobiology of Disease, 2018, 113, 97-108.	4.4	27
34	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	6.2	111
35	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	3.6	35
36	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. Multiple Sclerosis and Related Disorders, 2017, 17, 217-219.	2.0	5

#	Article	IF	Citations
37	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	19
38	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences, 2017, 379, 236-240.	0.6	12
39	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. Journal of Neurology, 2016, 263, 1449-1451.	3.6	2
40	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. European Neurology, 2016, 76, 62-68.	1.4	4
41	Retinopathy during interferon-Î² treatment for multiple sclerosis: case report and review of the literature. Journal of Neurology, 2016, 263, 422-427.	3.6	12
42	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Brain Research, 2015, 1621, 205-213.	2.2	30
43	Infliximab monotherapy for neuro-BehÃ§et's disease: A case report. Journal of the Neurological Sciences, 2014, 347, 389-390.	0.6	8
44	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. European Journal of Neurology, 2014, 21, 648-653.	3.3	17
45	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology, 2012, 79, 1182-1184.	1.1	27